Research Progress in Drug Application and Treatment of Breast Cancer Organoids

Yitong Lin

doi:10.54097/8dg1mx62

Authors

Yitong Lin

DOI:

https://doi.org/10.54097/8dg1mx62

Keywords:

Breast cancer organoids; drug screening; drug therapy.

Abstract

Background: In recent years, the incidence of breast cancer (BC) is high and on the rise. Organoids, as a new in vitro 3D culture model, play a huge role in BC treatment and drug development. Objective: To summarize the domestic and foreign research experience in BC organoids in drug screening, in order to provide new ideas for BC treatment.Summary: This article briefly summarized the mechanism of action of commonly used drugs for BC, including trastuzumab, tamoxifen, olaparib, paclitaxel, pembrolizumab, and the effects of HER-2 drugs and CDK4/6 inhibitors on BC organoids, clarified the importance of BC organoids, and drew the conclusion that more accurate treatment could be achieved by using this model. The successful establishment of papillary carcinoma organoids further demonstrated the feasibility of cultured 3D models in vitro. On this basis, drug sensitivity tests for different drugs were conducted, and it was concluded that fluvestrant had the best anticancer effect, thus proving that BC organoids played an important role in drug screening. In addition, organoid technology also has a good effect in the treatment of Triple-negative breast cancer (TNBC). Using this model for large-scale drug detection, four compounds including papirinestat, patinib, JIB-04 and TAK-901 showed effective activity on TNBC organoids, indicating that organoids can promote drug discovery. It is concluded that BC organoids are a potential therapeutic model, and the development of this technology provides an innovative approach to treating BC.

Downloads

Download data is not yet available.

References

[1] Xu Shishuang. Research Progress on Trastuzumab-Targeted Therapy for HER2-Positive Breast Cancer [J]. Advances in Clinical Medicine, 2023, 13(7): 12031-12037.

[2] Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, De Bruyn T, Giltnane JM, Hartman SJ, Heidersbach AJ, Houtman R, Ingalla ER, Kategaya LS, Kleinheinz T, Li J, Martin SE, Modrusan Z, Nannini MA, Oeh J, Ubhayakar S, Wang X, Wertz IE, Young AE, Yu M, Sampath D, Hager JH, Friedman LS, Daemen A. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility [J]. Cell, 2019, 178: 949-963.e18.

[3] Lord CJ, Ashworth A. PARP Inhibitors: Synthetic Lethality in the Clinic [J]. Science (New York, N.Y.), 2017, 355(6330): 1152–1158.

[4] Alalawy AI. Key Genes and Molecular Mechanisms Related to Paclitaxel Resistance [J]. Cancer Cell International, 2024, 24: 244.

[5] Wang Wenchao, Wang Yu, Shi Lehua, Yin Zhengfeng. Programmed Death 1/Programmed Death Ligand 1 Signaling Pathway in Tumor Immunotherapy: An Update [J]. Academic Journal of Second Military Medical University, 2017, 38(9): 1190-1195.

[6] Maiturubai·Mirzakhmet, Kawi·Jumai, Dilimulati·Aishmutula, Li Huifang, Aliqing·Abdusalam. Research Progress and Future Prospects of HER-2 Low-Expressing Breast Cancer [J]. Advances in Clinical Medicine, 2023, 13(10): 16593-16601.

[7] Zhang Ning, Yang Hui, Wang Peng. Progress in the Application of Organoids in Cancer Research, Drug Screening, and Precision Therapy [J]. Journal of Peking University (Medical Edition), 2022, (005): 054.

[8] Annals of Oncology, 2022, 16(suppl_1): 100102-100102.

[9] Liang Minting, Yang Ciqiu, Wang Kun. Research Progress of CDK4/6 Inhibitor in Breast Cancer [J]. Journal of Evidence-Based Medicine, 2023, 23(2): 65-73.

[10] Hanker AB, Chatterjee S, Wang Y, Ye D, Sudhan DR, Larsen BM, Smith LC, Zhang Y, Kandagatla V, Majmudar K, Renzulli E, Mendiratta S, Blackwell K, Welm AL, Sahoo S, Unni N, Lewis CM, Wang T, Salahudeen AA, Arteaga CL. Abstract PD2-01: A Platform of CDK4/6 Inhibitor-Resistant Patient-Derived Breast Cancer Organoids Illuminates Mechanisms of Resistance and Therapeutic Vulnerabilities [J]. Cancer Research, 2022, 82(4_Supplement): PD2–01.

[11] Li X, Pan B, Song X, Li N, Zhao D, Li M, Zhao Z. Breast Cancer Organoids from a Patient with Giant Papillary Carcinoma as a High-Fidelity Model [J]. Cancer Cell International, 2020, 20: 86.

[12] Zhao Shinan, Tian Congkun. Current Status and Progress of Treatment for Triple-Negative Breast Cancer [J]. Advances in Clinical Medicine, 2024, 14(4): 1797-1800.

[13] Rao X, Qiao Z, Yang Y, Deng Y, Zhang Z, Yu X, Guo X. Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer Through 3D Organoid Drug Screening [J]. Pharmaceuticals (Basel), 2024, 17(2): 225.